Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H23FN4O3 |
Molecular Weight | 386.42 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(N2C[C@@H](N)C3(CC3)C2)C(F)=C(N)C4=C1N(C=C(C(O)=O)C4=O)C5CC5
InChI
InChIKey=LEILBPMISZFZQK-GFCCVEGCSA-N
InChI=1S/C20H23FN4O3/c1-9-16-13(18(26)11(19(27)28)6-25(16)10-2-3-10)15(23)14(21)17(9)24-7-12(22)20(8-24)4-5-20/h6,10,12H,2-5,7-8,22-23H2,1H3,(H,27,28)/t12-/m1/s1
Molecular Formula | C20H23FN4O3 |
Molecular Weight | 386.42 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14613952Curator's Comment: description was created based on several sources, including http://adisinsight.springer.com/drugs/800006301 | http://www.ncbi.nlm.nih.gov/pubmed/12957636 | https://www.ncbi.nlm.nih.gov/pubmed/15608441
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14613952
Curator's Comment: description was created based on several sources, including http://adisinsight.springer.com/drugs/800006301 | http://www.ncbi.nlm.nih.gov/pubmed/12957636 | https://www.ncbi.nlm.nih.gov/pubmed/15608441
Olamufloxacin (HSR-903) is an oral fluoroquinolone antimicrobial agent which has been reported to have a potent activity against respiratory pathogens, such as Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Klebsiella pneumoniae, Staphylococcus aureus, Chlamydia spp. and Legionella spp., as well. Olamufloxacin inhibits DNA gyrase from the susceptible and resistant bacterial strains. It has been shown that olamufloxacin possesses a more potent antibacterial activity against potential respiratory pathogens compared with other quinolone derivatives. An oral formulation of olamufloxacin was undergoing phase III for Bacterial infections in Japan (Discontinued).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10381759
Curator's Comment: Known to be CNS penetrant in rats. Human data is not available. Tissue-to-plasma concentration ratio (Kp) in brain is extremely low, 0.11, demonstrating very poor distribution to the brain compared with other tissues. The blood-brain barrier permeability coefficient of [14C]Olamufloxacin ([14C]HSR-903) at a very low concentration (5 μm) was 10.5 μl/min/g. When the concentration of HSR-903 was increased to 20 or 50 mM, the permeability coefficient was increased 3- to 4-fold.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9087506
Curator's Comment: As of 2002, Hokuriku Seiyaku Co., Ltd. (Japan) was acquired by Abbott Laboratories.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311224 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15608441 |
20.7 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
|||
Curative | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro and in vivo antichlamydial activities of HSR-903, a new fluoroquinolone antibiotic. | 1997 Apr |
|
In vitro activity of HSR-903, a new quinolone. | 1997 Jun |
|
In-vitro antimicrobial activity of HSR-903, a new fluoroquinolone, against clinical isolates of Neisseria gonorrhoeae with quinolone resistance-associated alterations in GyrA and ParC. | 1997 Sep |
|
Hepatobiliary transport kinetics of HSR-903, a new quinolone antibacterial agent. | 1998 Nov |
|
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. | 1999 Dec |
|
The in vivo activity of olamufloxacin (HSR-903) in systemic and urinary tract infections in mice. | 2001 Jul |
|
In vitro and in vivo activity of olamufloxacin (HSR-903) against Legionella spp. | 2003 Dec |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10348779
The tablet form of Olamufloxacin (HSR-903) containing 100 mg of active ingredient.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9174193
Olamufloxacin was tested against different strains of chlamydia. The MICs for standard strains were 0.016 to 0.063 mg/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:14:33 GMT 2023
by
admin
on
Sat Dec 16 16:14:33 GMT 2023
|
Record UNII |
LJG8KL1435
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C795
Created by
admin on Sat Dec 16 16:14:34 GMT 2023 , Edited by admin on Sat Dec 16 16:14:34 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
477670
Created by
admin on Sat Dec 16 16:14:34 GMT 2023 , Edited by admin on Sat Dec 16 16:14:34 GMT 2023
|
PRIMARY | |||
|
LJG8KL1435
Created by
admin on Sat Dec 16 16:14:34 GMT 2023 , Edited by admin on Sat Dec 16 16:14:34 GMT 2023
|
PRIMARY | |||
|
SUB03495MIG
Created by
admin on Sat Dec 16 16:14:34 GMT 2023 , Edited by admin on Sat Dec 16 16:14:34 GMT 2023
|
PRIMARY | |||
|
C84030
Created by
admin on Sat Dec 16 16:14:34 GMT 2023 , Edited by admin on Sat Dec 16 16:14:34 GMT 2023
|
PRIMARY | |||
|
C106426
Created by
admin on Sat Dec 16 16:14:34 GMT 2023 , Edited by admin on Sat Dec 16 16:14:34 GMT 2023
|
PRIMARY | |||
|
100000085936
Created by
admin on Sat Dec 16 16:14:34 GMT 2023 , Edited by admin on Sat Dec 16 16:14:34 GMT 2023
|
PRIMARY | |||
|
7740
Created by
admin on Sat Dec 16 16:14:34 GMT 2023 , Edited by admin on Sat Dec 16 16:14:34 GMT 2023
|
PRIMARY | |||
|
167887-97-0
Created by
admin on Sat Dec 16 16:14:34 GMT 2023 , Edited by admin on Sat Dec 16 16:14:34 GMT 2023
|
PRIMARY | |||
|
CHEMBL2078925
Created by
admin on Sat Dec 16 16:14:34 GMT 2023 , Edited by admin on Sat Dec 16 16:14:34 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
TARGET ORGANISM->INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|